Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer

References

• Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. 2003. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). American Journal of Clinical Oncology 26:358–362.
   PubMed Web of Science ®Google Scholar
• Baur M, Schernhammer E, Gneist M, Sevelda P, Speiser P, Hudec M, et al. 2005. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer. British Journal of Cancer 92:1019–1025.
   PubMed Web of Science ®Google Scholar
• Bozkaya Y, Doğan M, Umut Erdem G, Tulunay G, Uncu H, Arık Z, et al. 2017. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer. Journal of Obstetrics and Gynaecology 37:649–654.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 68:394–424.
   PubMed Web of Science ®Google Scholar
• [CTCAE] Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2010 [online]. Available from: http://purl.stanford.edu/nw036fx4646
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 45:228–247.
   PubMed Web of Science ®Google Scholar
• Fellows of the American Society of Health-System Pharmacists. 2016. ASHP practitioner recognition program-2016. American Journal of Health System Pharmacy 73:1010.
   PubMedGoogle Scholar
• Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. 2008. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of Clinical Oncology 26:890–896.
   PubMed Web of Science ®Google Scholar
• Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, et al. 2011. Clinical trials in recurrent ovarian cancer. International Journal of Gynecological Cancer 21:771–775.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, Rackoff W. 2004. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecologic Oncology 95:1–8.
   PubMed Web of Science ®Google Scholar
• Hoskins PJ, Swenerton KD. 1994. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. Journal of Clinical Oncology 12:60–63.
   PubMed Web of Science ®Google Scholar
• Kavanagh JJ, Tresukosol D, De Leon CG, Edwards CL, Freedman RS, Hord M, et al. 1995. Phase II study of prolonged oral etoposide in refractory ovarian cancer. International Journal of Gynecological Cancer 5:351–354.
   PubMed Web of Science ®Google Scholar
• Kumar A, Le N, Santos J, Hoskins P. 2018. Chemotherapy is of value in second line and beyond, relapsed high-grade, serous epithelial ovarian cancer: an analysis of outcomes obtained with oral etoposide. American Journal of Clinical Oncology 41:379–384.
   PubMed Web of Science ®Google Scholar
• Lan CY, Wang Y, Xiong Y, Li JD, Shen JX, Li YF, et al. 2018. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncology 19:1239–1246.
   PubMed Web of Science ®Google Scholar
• Markman M. 2011. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Management and Research 3:219–225.
   PubMedGoogle Scholar
• Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. 1991. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology 9:389–393.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Katsumata N, Saito I, Shibata T, Konishi I, Fukuda H, et al. 2012. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503. Japanese Journal of Clinical Oncology 42:222–225.
   PubMed Web of Science ®Google Scholar
• Moosavi AS, Gilani MM, Tehranian A, Esfahani JK. 2004. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy. Journal of Obstetrics and Gynaecology 24:292–293.
   Google Scholar
• Morgan RJ Jr., Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, et al. 2016. Ovarian cancer, version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 14:1134–1163.
   PubMed Web of Science ®Google Scholar
• Ozols RF. 1999. Oral etoposide for the treatment of recurrent ovarian cancer. Drugs 58(Suppl. 3):43–49.
   PubMedGoogle Scholar
• Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, et al. 2003. Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer. International Journal of Gynecological Cancer 13(Suppl. 2):144–148.
   PubMedGoogle Scholar
• Rose PG, Blessing JA, Mayer AR, Homesley HD. 1998. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 16:405–410.
   PubMed Web of Science ®Google Scholar
• Ross W, Rowe T, Glisson B, Yalowich J, Liu L. 1984. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Research 44:5857–5860.
   PubMed Web of Science ®Google Scholar
• Thavaramara T, Tangjitgamol S, Manusirivithaya S, Leelahakorn S. 2009. Oral etoposide for refractory or recurrent epithelial ovarian cancer. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet 92:1397–1405.
   PubMedGoogle Scholar